Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationHodgkin Disease
Dr. Bethany Sleckman, MD
NPI1861814386PAC ID1153541438
- Medicare services, 2024
- 769
- Medicare patients, 2024
- 367
- Part D claims, 2024
- 2,057
- Publications
- 4
- Clinical trials
- 10
- Practice address
- 615 New Ballas Road, Saint Louis, MO 63141
- Practice phone
- Call (314) 251-6000
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Sleckman's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Bethany Sleckman is a medical oncologist in Saint Louis, Missouri
Dr. Sleckman practices at Mercy Hospital St. Louis in Saint Louis, Missouri, part of Mercy.
Dr. Sleckman's NPI, 1861814386, was assigned on January 17, 2014. Dr. Sleckman graduated from Duke University School of Medicine in 1990. Dr. Sleckman holds Missouri license 2002027895.
NPI and contact details
- NPI
- 1861814386NPI Registry (opens in a new tab)
- Medicare PAC ID
- 1153541438
- NPI enumeration date
- January 17, 2014
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Practice phone
- (314) 251-6000
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 62
- Medical school graduation
- 1990
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Bethany Sleckman practices at Mercy Hospital St. Louis in Saint Louis, Missouri
Dr. Sleckman's primary practice is Mercy Hospital St. Louis, at 615 New Ballas Road, Saint Louis, MO 63141 in St. Louis County. The practice phone is (314) 251-6000.
- Mercy Hospital St. Louis615 New Ballas Road, Saint Louis, MO 63141 · St. Louis CountyPhone(314) 251-6000
Source: Dmand AI Affiliation Data
Dr. Bethany Sleckman is affiliated with 7 sites of care and 2 medical groups
Dr. Sleckman's primary practice is Mercy Hospital St. Louis in Saint Louis, Missouri, part of Mercy. Dr. Sleckman is also affiliated with Mercy Hospital South. The medical group on file is Mercy Hospital St. Louis. Dmand AI also links Dr. Sleckman to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.
Mercy Hospital SouthMercy Hospital St. Louis3 hospitalsNames with a free account2 group practices and clinicsNames with a free account1 medical groupName with a free account
See all 9 affiliations for Dr. SleckmanSources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Bethany Sleckman's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sleckman practices, 7 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Mercy Hospital St. Louis | Available with a free account |
| +6 more sites and 1 medical group | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every hospital where Dr. Sleckman practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across Mercy and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Bethany Sleckman is one of 120 medical oncologists in Missouri
Medical oncology is Dr. Sleckman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Sleckman is licensed in Missouri.
Specialties and state licenses
- Medical oncology, MissouriPrimary
Medical oncologists near Dr. Sleckman
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
120medical oncologists in Missouri86medical oncologists in Saint Louis4medical oncologists at Mercy Hospital St. Louis
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Bethany Sleckman billed Medicare for 769 services in 2024
CMS data shows 769 Medicare services from Dr. Sleckman across 8 procedure codes in 2024, for 367 Medicare patients. Medicare paid $41,305 for them.
Medicare services, 2024769
Medicare patients367
Paid by Medicare$41,305
Procedure codes8
Dr. Sleckman's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 6262024: 76923%
Where Dr. Sleckman's Medicare services took place, 2024
- In an office54070%
- In a facility22930%
Dr. Sleckman compared with the Missouri median for medical oncologists, 2024
- Dr. Sleckman
- Missouri median
- Medicare services
- 769vs 1,24638% below
- Medicare patients
- 367vs 22464% above
- Part D claims
- 1,787vs 5603.2 times
Medians across 125 medical oncologists in Missouri with Dmand AI profiles that report each measure.
Dr. Sleckman's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Sleckman?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Sleckman and other medical oncologists in Missouri.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Bethany Sleckman treated 367 Medicare patients in 2024, average age 74
CMS counts 367 Medicare patients who saw Dr. Sleckman in 2024. The largest group is 65 to 74, with 182 patients. 75% of them have high cholesterol, and 73% have cancer. 3% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.
Across all payers, Dmand AI patient panel data puts Dr. Sleckman's median patient age at 71, with 81% women.
Medicare patients, 2024367
Average age74
Average risk score1.42
Also on Medicaid3%
Dr. Sleckman's Medicare patients by age, 2024
Dr. Sleckman's Medicare patients by sex, 2024
- Women31084%
- Men5716%
Chronic conditions among Dr. Sleckman's Medicare patients, 2024
- High cholesterol75%
- Cancer73%
- High blood pressure71%
- Arthritis51%
- Chronic kidney disease29%
- Osteoporosis28%
- Anxiety27%
- Mood disorders25%
Share of Medicare patients with each condition. A patient can have several.
Dr. Sleckman's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 71
Patient panel by sex, all payers
- Women81%
- Men18%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Bethany Sleckman wrote 2,057 Medicare Part D claims in 2024
In 2024, Dr. Sleckman wrote 2,057 Medicare Part D claims for 441 patients. 82% of them were for generic drugs. CMS names the drug for 1,787 of them, across 36 drugs with 11 or more claims each, at $3,688,773 in total drug cost. In 2023, CMS named 1,162 claims across 23 drugs.
Part D claims, 20242,057
Drugs named by CMS36
Total drug cost$3.7M
Part D patients441
Dr. Sleckman's Part D claims by kind of drug, 2024
- Generic1,679 claims82%
- Brand-name378 claims18%
Dr. Sleckman's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Sleckman's Part D claims, 2024
- Opioids3%60 of 2,057 claims
- Antibiotics2%50 of 2,057 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 1,1622024: 1,78754%
Drugs named by CMS: 36 in 2024, 23 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
How Dr. Bethany Sleckman takes part in Medicare
Dr. Sleckman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.
- Accepts Medicare assignment
- Yes
Source: Doctors and Clinicians National Downloadable File (CMS)
For MedTech and pharma teams
Find medical oncologists like Dr. Sleckman by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Bethany Sleckman has 4 publications on record
Dmand AI links 4 papers to Dr. Sleckman, published from 2011 to 2022. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors and Sirolimus. Dr. Sleckman's most frequent co-authors are Daniel V. Catenacci, Deirdre Jill Cohen, MD and Kenneth S. Cohen.
Papers4
Years published2011 to 2022
Dr. Sleckman's papers by year, 2011 to 2022
Topics Dr. Sleckman writes about most
- Antineoplastic Combined Chemotherapy Protocols
- Protein Kinase Inhibitors
- Sirolimus
- TOR Serine-Threonine Kinases
Dr. Sleckman's most frequent co-authors
Recent publications by Dr. Sleckman
Antineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCetuximab
Colorectal NeoplasmsDasatinibLiver Neoplasms
See who Dr. Sleckman researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Sleckman works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Bethany Sleckman has worked on 10 clinical trials
Dmand AI links Dr. Sleckman to 10 clinical trials, 6 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Histiocytosis, Langerhans-Cell, Hepatoblastoma and Down Syndrome. National Cancer Institute (NCI) sponsors the most, 6.
Clinical trials with Dr. Sleckman by phase
- NonePhase 1: no trials
- 6Phase 2: 6 trials
- 4Phase 3: 4 trials
- NonePhase 4: no trials
Conditions in Dr. Sleckman's trials
- Histiocytosis, Langerhans-Cell
- Hepatoblastoma
- Down Syndrome
- Leukemia, Biphenotypic, Acute
- Medulloblastoma
Investigators on the most trials with Dr. Sleckman
- Wendy L. Woods-Swafford, MD10 shared trials
- Mark Jeffrey Mogul, MD9 shared trials
- Hardeo Karamchand Panchoosingh, MD8 shared trials
Recent clinical trials with Dr. Sleckman
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (opens in a new tab)
Active, not recruitingPhase 2
Histiocytosis, Langerhans-CellHepatoblastomaUlixertinib
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (opens in a new tab)
Active, not recruitingPhase 2
Histiocytosis, Langerhans-CellHepatoblastomaEnsartinib
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma (opens in a new tab)
Active, not recruitingPhase 2
MedulloblastomaNeuroectodermal Tumors, PrimitiveRadiation TherapyCisplatinCyclophosphamide
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (opens in a new tab)
Active, not recruitingPhase 2
Histiocytosis, Langerhans-CellHepatoblastomaLarotrectinib Sulfate
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (opens in a new tab)
Active, not recruitingPhase 3
Leukemia, Biphenotypic, AcutePrecursor T-Cell Lymphoblastic Leukemia-LymphomaImatinib MesylateCalaspargase PegolCyclophosphamide
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Bethany Sleckman received $32,670 in industry payments from 2016 to 2025
CMS Open Payments shows 1,326 general payments to Dr. Sleckman from 87 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 76% of the total. Pfizer Inc. paid the most, $8,236. It also lists 8 research payments totaling $7,200 from 2018 to 2022.
General payments to Dr. Sleckman by program year, 2016 to 2025
General payments to Dr. Sleckman by kind, 2016 to 2025
$32.7Kin total
- Food and beverage$24,85576%
- Speaker and faculty fees$5,78018%
- Travel and lodging$1,5825%
- Education$4541%
Companies that paid Dr. Sleckman the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Bethany Sleckman graduated from Duke University School of Medicine
Dr. Sleckman graduated from Duke University School of Medicine in 1990.
- Medical school
Source: Dmand AI Professional Profile Data
Sources for Dr. Bethany Sleckman's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Bethany Sleckman
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Bethany Sleckman's NPI number?
Dr. Bethany Sleckman's NPI number is 1861814386. It was assigned on January 17, 2014, and it is active in the NPI Registry.
What kind of doctor is Dr. Bethany Sleckman?
Dr. Bethany Sleckman is a medical oncologist in Saint Louis, Missouri. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Bethany Sleckman practice?
Dr. Sleckman practices at 615 New Ballas Road, Saint Louis, MO 63141. Dr. Sleckman's primary practice is Mercy Hospital St. Louis in Saint Louis, Missouri, part of Mercy. Dmand AI also links Dr. Sleckman to 3 hospitals, 2 group practices and clinics and 1 medical group.
What is Dr. Bethany Sleckman's office phone number?
The practice phone on file for Dr. Sleckman is (314) 251-6000.
What is Dr. Bethany Sleckman's medical license number?
Dr. Sleckman holds Missouri license 2002027895.
Which hospitals is Dr. Bethany Sleckman affiliated with?
Dr. Sleckman practices at Mercy Hospital St. Louis in Saint Louis, Missouri. Dr. Sleckman is also affiliated with Mercy Hospital South. Dmand AI links Dr. Sleckman to 3 more hospitals.
What medical group is Dr. Bethany Sleckman part of?
Dr. Sleckman is linked to Mercy Hospital St. Louis. Dmand AI links Dr. Sleckman to 1 more medical group.
Does Dr. Bethany Sleckman accept Medicare?
Yes. CMS data shows Dr. Sleckman billed Medicare for 769 services in 2024, and Dr. Sleckman accepts Medicare assignment.
How many Medicare patients does Dr. Bethany Sleckman see?
CMS counts 367 Medicare patients who saw Dr. Sleckman in 2024, with an average age of 74.
What services does Dr. Bethany Sleckman bill to Medicare?
In 2024, Dr. Sleckman's most billed Medicare services were office visit, established patient (99213), office visit, established patient (99214) and office visit, established patient (99212).
Show 6 more questionsShow fewer questions
Where did Dr. Bethany Sleckman go to medical school?
Dr. Sleckman graduated from Duke University School of Medicine in 1990.
What drugs does Dr. Bethany Sleckman prescribe most?
In 2024 Medicare Part D data, Dr. Sleckman's most prescribed drugs by claims were Letrozole, Tamoxifen Citrate and Anastrozole.
Has Dr. Bethany Sleckman received payments from drug or device companies?
CMS Open Payments shows $32,670 in general payments to Dr. Sleckman from 87 companies from 2016 to 2025. The largest total came from Pfizer Inc.
How long has Dr. Bethany Sleckman been practicing?
Dr. Sleckman graduated from medical school in 1990, 36 years ago.
Does Dr. Bethany Sleckman do research?
Dmand AI links 4 publications to Dr. Sleckman, published from 2011 to 2022. Dr. Sleckman has worked on 10 clinical trials.
Who does Dr. Bethany Sleckman publish with?
Dr. Sleckman's most frequent co-authors are Daniel V. Catenacci (1 shared paper), Deirdre Jill Cohen, MD (1 shared paper) and Kenneth S. Cohen (1 shared paper).
Selling to medical oncology practices?
See medical oncologists in Missouri by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card